Avenzo Therapeutics Secures $60 Million Series B to Advance Oncology Breakthroughs
October 3, 2025, 3:41 am
Avenzo Therapeutics secured $60 million in Series B funding. This propels their oncology pipeline. The San Diego biotech now totals $446 million raised. OrbiMed and SR One led the round. New investor Longwood Fund joined. Key existing backers also participated. Funds advance four clinical-stage assets. These include small molecules and advanced ADCs. Avenzo targets high unmet medical needs in cancer. Their innovative therapies offer new hope.
San Diego’s Avenzo Therapeutics is making significant strides. The clinical-stage biotechnology firm recently announced a $60 million Series B financing. This crucial funding closed on September 22, 2025. It marks a pivotal moment for cancer drug development. The biotech sector watched closely.
This investment builds on prior success. Avenzo secured $386 million in Series A/A-1 financing last November. The new Series B round pushes total capital raised to $446 million. This substantial backing underscores deep investor confidence. It validates Avenzo's innovative approach to oncology. Such financial strength is rare for emerging biotechs.
OrbiMed and SR One spearheaded the latest funding round. Their leadership signals strong belief in Avenzo’s potential. Longwood Fund joined as a new strategic investor. This expanded syndicate brings fresh expertise and broader market reach. Numerous existing investors also recommitted their capital. These included prominent names like Foresite Capital, Lilly Asia Ventures, and Surveyor Capital, a Citadel company. New Enterprise Associates, Deep Track Capital, Sofinnova Investments, Sands Capital, INCE Capital, TF Capital, Delos Capital, and Quan Capital also participated. Their continued support empowers Avenzo's mission and future trajectory.
Proceeds from the Series B financing have a clear, vital purpose. They will accelerate Avenzo's pipeline progression. The company is advancing several potential best-in-class oncology drug candidates. This capital infusion ensures robust progress through critical development phases. It supports ongoing, expensive clinical studies. It enables future milestones, bringing new therapies closer to patients.
Avenzo Therapeutics focuses intently on patients. The company develops next-generation oncology therapies. These advanced treatments aim to address critical unmet medical needs. Their headquarters in San Diego positions them within a vibrant biotech hub. The team is dedicated to innovative cancer solutions. Their work promises to revolutionize patient care.
The pipeline features diverse therapeutic modalities. Small molecule inhibitors form a core component. These compounds disrupt specific cancer pathways. AVZO-021 targets CDK2. It is Avenzo's lead drug candidate. CDK2 plays a key role in cell cycle regulation. Uncontrolled cell cycles drive cancer growth. Studies for advanced solid tumors are now underway. It is also explored in combinations for HR+/HER2- metastatic breast cancer. This aggressive cancer type needs new options.
AVZO-023 inhibits CDK4. This compound is also in Phase 1/2 trials. It addresses advanced solid tumors. Its potential in HR+/HER2- metastatic breast cancer is also being assessed. Both AVZO-021 and AVZO-023 are novel, highly potent, and selective inhibitors. This selectivity minimizes off-target effects. It potentially improves safety profiles.
Avenzo also pioneers antibody-drug conjugates (ADCs). These advanced therapies deliver potent cytotoxic agents directly to cancer cells. This targeted delivery spares healthy tissue. AVZO-1418 is their first ADC candidate. It is an EGFR/HER3 bispecific ADC. A Phase 1/2 study is evaluating its efficacy. This targets advanced solid tumors. The approach promises enhanced tumor targeting. It aims for significantly reduced systemic toxicity compared to traditional chemotherapy.
A second ADC, AVZO-103, is also under development. This Nectin4/TROP2 bispecific ADC shows strong promise. These targets are overexpressed in many solid tumors. Avenzo plans its Phase 1/2 study initiation in 2025. This will focus on patients with advanced solid tumors. These ADCs represent a significant leap in targeted cancer therapy. They embody Avenzo's commitment to cutting-edge science.
Avenzo's pipeline growth has been rapid and impressive. The company transitioned from one to four clinical-stage assets this year. This swift expansion highlights effective research and development strategies. It demonstrates efficient clinical progression. Each asset holds unique potential. Each targets specific, validated cancer pathways. This multi-pronged strategy maximizes the chance of clinical success.
The successful Series B round reinforces Avenzo’s market position. It strengthens its ability to compete in the fierce biotech landscape. The sector is characterized by high risk and high reward. Sustained, significant funding is crucial for innovation and long-term viability. Avenzo now possesses substantial resources. These resources fuel its ambitious development plans and clinical execution.
Investment in oncology remains robust globally. Cancer research is a universal priority. Breakthrough therapies are desperately needed for millions of patients. Avenzo’s work contributes directly to this critical effort. Their drug candidates aim for "best-in-class" status. This signifies high aspirations for superior patient outcomes and improved quality of life.
The biotech ecosystem, particularly in San Diego, benefits immensely from such investments. San Diego continues to be a vibrant hotbed for life science innovation and entrepreneurial spirit. Avenzo's progress reflects this dynamic environment and its strong scientific foundation. The company's future looks exceedingly promising. Their therapies could redefine several cancer treatment paradigms.
This substantial capital ensures Avenzo’s momentum continues unabated. It supports rigorous clinical trials, ensuring safety and efficacy. It funds necessary regulatory processes, navigating complex pathways. Ultimately, it brings potentially life-saving treatments closer to the patients who need them most. Avenzo Therapeutics is poised for further, transformative advancements. Their dedication actively shapes the future of oncology.
San Diego’s Avenzo Therapeutics is making significant strides. The clinical-stage biotechnology firm recently announced a $60 million Series B financing. This crucial funding closed on September 22, 2025. It marks a pivotal moment for cancer drug development. The biotech sector watched closely.
This investment builds on prior success. Avenzo secured $386 million in Series A/A-1 financing last November. The new Series B round pushes total capital raised to $446 million. This substantial backing underscores deep investor confidence. It validates Avenzo's innovative approach to oncology. Such financial strength is rare for emerging biotechs.
OrbiMed and SR One spearheaded the latest funding round. Their leadership signals strong belief in Avenzo’s potential. Longwood Fund joined as a new strategic investor. This expanded syndicate brings fresh expertise and broader market reach. Numerous existing investors also recommitted their capital. These included prominent names like Foresite Capital, Lilly Asia Ventures, and Surveyor Capital, a Citadel company. New Enterprise Associates, Deep Track Capital, Sofinnova Investments, Sands Capital, INCE Capital, TF Capital, Delos Capital, and Quan Capital also participated. Their continued support empowers Avenzo's mission and future trajectory.
Proceeds from the Series B financing have a clear, vital purpose. They will accelerate Avenzo's pipeline progression. The company is advancing several potential best-in-class oncology drug candidates. This capital infusion ensures robust progress through critical development phases. It supports ongoing, expensive clinical studies. It enables future milestones, bringing new therapies closer to patients.
Avenzo Therapeutics focuses intently on patients. The company develops next-generation oncology therapies. These advanced treatments aim to address critical unmet medical needs. Their headquarters in San Diego positions them within a vibrant biotech hub. The team is dedicated to innovative cancer solutions. Their work promises to revolutionize patient care.
The pipeline features diverse therapeutic modalities. Small molecule inhibitors form a core component. These compounds disrupt specific cancer pathways. AVZO-021 targets CDK2. It is Avenzo's lead drug candidate. CDK2 plays a key role in cell cycle regulation. Uncontrolled cell cycles drive cancer growth. Studies for advanced solid tumors are now underway. It is also explored in combinations for HR+/HER2- metastatic breast cancer. This aggressive cancer type needs new options.
AVZO-023 inhibits CDK4. This compound is also in Phase 1/2 trials. It addresses advanced solid tumors. Its potential in HR+/HER2- metastatic breast cancer is also being assessed. Both AVZO-021 and AVZO-023 are novel, highly potent, and selective inhibitors. This selectivity minimizes off-target effects. It potentially improves safety profiles.
Avenzo also pioneers antibody-drug conjugates (ADCs). These advanced therapies deliver potent cytotoxic agents directly to cancer cells. This targeted delivery spares healthy tissue. AVZO-1418 is their first ADC candidate. It is an EGFR/HER3 bispecific ADC. A Phase 1/2 study is evaluating its efficacy. This targets advanced solid tumors. The approach promises enhanced tumor targeting. It aims for significantly reduced systemic toxicity compared to traditional chemotherapy.
A second ADC, AVZO-103, is also under development. This Nectin4/TROP2 bispecific ADC shows strong promise. These targets are overexpressed in many solid tumors. Avenzo plans its Phase 1/2 study initiation in 2025. This will focus on patients with advanced solid tumors. These ADCs represent a significant leap in targeted cancer therapy. They embody Avenzo's commitment to cutting-edge science.
Avenzo's pipeline growth has been rapid and impressive. The company transitioned from one to four clinical-stage assets this year. This swift expansion highlights effective research and development strategies. It demonstrates efficient clinical progression. Each asset holds unique potential. Each targets specific, validated cancer pathways. This multi-pronged strategy maximizes the chance of clinical success.
The successful Series B round reinforces Avenzo’s market position. It strengthens its ability to compete in the fierce biotech landscape. The sector is characterized by high risk and high reward. Sustained, significant funding is crucial for innovation and long-term viability. Avenzo now possesses substantial resources. These resources fuel its ambitious development plans and clinical execution.
Investment in oncology remains robust globally. Cancer research is a universal priority. Breakthrough therapies are desperately needed for millions of patients. Avenzo’s work contributes directly to this critical effort. Their drug candidates aim for "best-in-class" status. This signifies high aspirations for superior patient outcomes and improved quality of life.
The biotech ecosystem, particularly in San Diego, benefits immensely from such investments. San Diego continues to be a vibrant hotbed for life science innovation and entrepreneurial spirit. Avenzo's progress reflects this dynamic environment and its strong scientific foundation. The company's future looks exceedingly promising. Their therapies could redefine several cancer treatment paradigms.
This substantial capital ensures Avenzo’s momentum continues unabated. It supports rigorous clinical trials, ensuring safety and efficacy. It funds necessary regulatory processes, navigating complex pathways. Ultimately, it brings potentially life-saving treatments closer to the patients who need them most. Avenzo Therapeutics is poised for further, transformative advancements. Their dedication actively shapes the future of oncology.